2023
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Djimde M, Kayentao K, Tshiongo J, Fofana B, Arama C, Sirima S, Ouedraogo J, Beavogui A, Sagara I, Dicko A, Mens P, Schallig H, Djimde A. Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. The Journal Of Infection In Developing Countries 2023, 17: 1337-1345. PMID: 37824364, DOI: 10.3855/jidc.17089.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyNormal neutrophil countsPolymorphonuclear neutrophilsDay 28Neutropenia groupPyronaridine-ArtesunateNeutrophil countNeutrophil levelsDifferent artemisinin-based combination therapiesRole of PMNsCombination therapy efficacyP. falciparum parasitemiaPositive blood smearPlasmodium falciparum parasitemiaLevels of neutrophilsAL armASAQ armProspective longitudinalRecurrent parasitemiaCombination therapyNeutrophil rateNeutropenia patientsNormal ratePatientsPathogen clearanceImpact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel J, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko J, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon K, Goetz M, Haddad T, Iwata H, Jassem J, Lee S, Linderholm B, Los M, Mamounas E, Miller K, Morris P, Munzone E, Gal-Yam E, Ring A, Shepherd L, Singer C, Thomssen C, Tseng L, Valagussa P, Winer E, Wolff A, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck A, DeMichele A, Gnant M, Cameron D, El-Abed S, Rugo H, Steger G, Traina T, Werutsky G, Wolmark N. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. Journal Of Clinical Oncology 2023, 41: 5118-5130. PMID: 37556775, DOI: 10.1200/jco.23.00126.Peer-Reviewed Original ResearchConceptsImpact of BMIPALLAS trialBMI categoriesHigher BMIEarly hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerAddition of palbociclibEfficacy of palbociclibEarly treatment discontinuationRelative dose intensityTreatment discontinuation ratesDisease-free survivalSide effect profileMultivariable logistic regressionBreast cancer riskSignificant decreaseNeutropenia ratesPalbociclib armEndocrine therapyTreatment discontinuationDiscontinuation ratesDose intensityEarly discontinuationNormal weightEfficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Platzbecker U, Della Porta M, Santini V, Zeidan A, Komrokji R, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Giuseppi A, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Shetty J, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. The Lancet 2023, 402: 373-385. PMID: 37311468, DOI: 10.1016/s0140-6736(23)00874-7.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesRed blood cell transfusion independenceEpoetin alfa groupErythropoiesis-stimulating agentsEpoetin alfaMyelodysplastic syndromeInterim analysisPrimary endpointAdverse eventsAlfa groupTransfusion independenceLower riskBody weightTreatment-emergent adverse eventsTreatment-related adverse eventsRed blood cell transfusionDurable clinical efficacyMean hemoglobin increaseMedian treatment exposureBlood cell transfusionCOVID-19 pneumoniaSubgroup of patientsWeeks of treatmentTreatment of anemiaAcute myeloid leukemiaPhase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodesNovel DNMT3B Mutation in a Patient with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome and a Bronchopulmonary Collateral Artery
Esmaeilzadeh H, Rezaei N, Aminorroaya A, Rayzan E, Shahkarami S, Seyedpour S, Zoghi S, Aryan Z, Somekh I, Rohlfs M, Klein C. Novel DNMT3B Mutation in a Patient with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome and a Bronchopulmonary Collateral Artery. Endocrine Metabolic & Immune Disorders - Drug Targets 2023, 23: 410-415. PMID: 35996251, DOI: 10.2174/1871530322666220822141722.Peer-Reviewed Original ResearchConceptsRecurrent respiratory infectionsFacial anomaliesDNMT3B mutationsRecurrent infectionsCollateral arteriesFamily historyRespiratory infectionsHistory of recurrent respiratory infectionsAssociated with recurrent infectionsCentromeric instabilityFamily history of consanguinityRare autosomal recessive disorderRecurrent episodes of pneumoniaMonthly intravenous immunoglobulinProphylactic trimethoprim-sulfamethoxazolePrimary immune deficiencyBone marrow studyLow-set earsPatent ductus arteriosusEvaluation of neutropeniaEpisodes of pneumoniaHistory of consanguinityMild facial anomaliesAutosomal recessive disorderSystolic cardiac murmur
2022
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie R, Odenike O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng W, Zhou Y, Hoffman D, Harb JG, Potluri J, Garcia‐Manero G. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. American Journal Of Hematology 2022, 98: 272-281. PMID: 36309981, PMCID: PMC10100228, DOI: 10.1002/ajh.26771.Peer-Reviewed Original ResearchConceptsMedian overall survivalMyelodysplastic syndromeOverall survivalTransfusion independenceHematological improvementTherapy failureHigh-risk myelodysplastic syndromeInternational Working Group criteriaHematological adverse eventsPhase 1b studyRefractory myelodysplastic syndromeStandard of careEfficacy of venetoclaxEffective therapeutic strategyFebrile neutropeniaMarrow CROral venetoclaxComplete remissionAdverse eventsMedian durationAzacitidine treatmentMedian timeMarrow responseMulticenter studyGroup criteriaLymphocyte Cytosolic Protein 1 (L-plastin) I232F Mutation Impairs Granulocytic Proliferation and Causes Neutropenia
Mahat U, Garg B, Yang CY, Mehta H, Hanna R, Rogers HJ, Flagg A, Ivanov AI, Corey SJ. Lymphocyte Cytosolic Protein 1 (L-plastin) I232F Mutation Impairs Granulocytic Proliferation and Causes Neutropenia. Blood Advances 2022, 6: 2581-2594. PMID: 34991157, PMCID: PMC9043934, DOI: 10.1182/bloodadvances.2021006398.Peer-Reviewed Original ResearchConceptsLymphocyte cytosolic protein 1Impaired cell motilityDiffuse intracellular localizationUnfolded protein responseCytosolic protein 1Level of genesCell cycle arrestActin regulationG2/M phaseNew genesActin cytoskeletonActin dynamicsCell motilityProtein responseSubcellular fractionationMutant formsF-actinIntracellular localizationWhole-exome sequencingCycle arrestHeLa cellsMissense mutationsHeterozygous missense mutationM phaseLCP1Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal Of Medicine 2022, 386: 942-950. PMID: 35263519, DOI: 10.1056/nejmoa2114663.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerSignificant overall survival benefitMedian overall survivalOverall survival benefitProgression-free survivalOverall survivalBreast cancerSurvival benefitHER2-negative advanced breast cancerKey secondary end pointProtocol-specified final analysisLonger progression-free survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Negative advanced breast cancerStratified log-rank testFirst-line ribociclibSecondary end pointsFirst-line therapyNew safety signalsPhase 3 trialGrowth factor receptor 2Kaplan-Meier methodLog-rank testFactor receptor 2
2021
CD16+CD163+ monocytes traffic to sites of inflammation during necrotizing enterocolitis in premature infants
Olaloye OO, Liu P, Toothaker JM, McCourt BT, McCourt CC, Xiao J, Prochaska E, Shaffer S, Werner L, Faculty U, Faculty U, Gringauz J, Good M, Goldsmith JD, An X, Wang F, Snapper SB, Shouval D, Chen K, Tseng G, Konnikova L. CD16+CD163+ monocytes traffic to sites of inflammation during necrotizing enterocolitis in premature infants. Journal Of Experimental Medicine 2021, 218: e20200344. PMID: 34269788, PMCID: PMC8289692, DOI: 10.1084/jem.20200344.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, CDAntigens, Differentiation, MyelomonocyticBlood VesselsCase-Control StudiesChemotaxisEnterocolitis, NecrotizingGastric MucosaGPI-Linked ProteinsHumansInfantInfant, NewbornIntestine, SmallMonocytesNeutropeniaNeutrophilsPhagocytosisReactive Oxygen SpeciesReceptors, Cell SurfaceReceptors, IgGSequence Analysis, RNASingle-Cell AnalysisConceptsSurgical NECCirculation of infantsDistinct neutrophil phenotypesSevere gastrointestinal complicationsAreas of inflammationSites of inflammationMonocyte trafficGastrointestinal complicationsPremature infantsNeutrophil phenotypeSevere inflammationInflammatory genesPotential biomarkersSingle-cell RNA sequencingOxygen species generationInflammationNovel subtypeBlood vesselsMass cytometryNECEnterocolitisMucosaInfantsMϕsSpecies generationNeutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality
Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer M, Mato A, Roeker L, Tallman M, Shah G, Daniyan A, Goldberg A. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia & Lymphoma 2021, 62: 1940-1948. PMID: 34180767, PMCID: PMC10080398, DOI: 10.1080/10428194.2021.1885664.Peer-Reviewed Original ResearchMeSH KeywordsAdultCOVID-19COVID-19 TestingHumansLeukemia, Myeloid, AcuteNeutropeniaRisk FactorsSARS-CoV-2ConceptsAdult acute myeloid leukemia patientsAcute myeloid leukemia patientsMemorial Sloan Kettering Cancer CenterCourse of COVID-19 infectionAssociated with increased odds of deathDiagnosis of AMLClinical course of COVID-19 infectionMyeloid leukemia patientsFlow nasal cannulaAssociated with increased oddsOdds of deathClinical courseHematologic malignanciesChronic leukemiaNasal cannulaLeukemia patientsCOVID-19 infectionMechanical ventilationPoor outcomeCancer CenterActive treatmentLeukemia subtypesRelated mortalityPatientsRisk factors
2020
Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials
Cargnin S, Shin J, Genazzani A, Nottegar A, Terrazzino S. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials. Cancer Chemotherapy And Pharmacology 2020, 86: 577-588. PMID: 33005979, DOI: 10.1007/s00280-020-04156-3.Peer-Reviewed Original ResearchConceptsObjective response rateHER2+ breast cancerRandomized Controlled TrialsBreast cancerTrastuzumab biosimilarsMeta-analysisTreatment of HER2+ breast cancerPhase III randomized controlled trialsIntention-to-treat populationMeta-analysis of randomized clinical trialsTreatment-emergent adverse effectsMeta-analysis of randomized controlled trialsRelative riskPurposeTo assess efficacyInfusion-related reactionsPer-protocol populationConclusionThis meta-analysisConfidence intervalsMantel-Haenszel methodMethodsA comprehensive searchRandomized clinical trialsSystematic reviewReference drugOverall survivalNo significant difference
2019
Treatment-Related Complications of Systemic Therapy and Radiotherapy
Jairam V, Lee V, Park HS, Thomas CR, Melnick ER, Gross CP, Presley CJ, Adelson KB, Yu JB. Treatment-Related Complications of Systemic Therapy and Radiotherapy. JAMA Oncology 2019, 5: 1028-1035. PMID: 30946433, PMCID: PMC6583836, DOI: 10.1001/jamaoncol.2019.0086.Peer-Reviewed Original ResearchConceptsTreatment-related complicationsOverall ED visitsAcute kidney injuryED visitsSystemic therapyInpatient admissionsEmergency departmentKidney injuryCommon complicationMAIN OUTCOMEUtilization Project Nationwide Emergency Department SampleFinancial burdenNationwide Emergency Department SampleHospital-related factorsClinical Modification codesEmergency Department SampleClinical Classification SoftwareTotal financial burdenInternational Statistical ClassificationOverall financial burdenHigh rateRelated Health ProblemsAcute complicationsStudy cohortNinth RevisionGuadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. The Lancet Haematology 2019, 6: e317-e327. PMID: 31060979, PMCID: PMC9012213, DOI: 10.1016/s2352-3026(19)30029-8.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeMyelodysplastic syndromeRefractory cohortAdverse eventsRefractory diseaseHypomethylating agentEastern Cooperative Oncology Group performance statusNorth American medical centersInternational Prognostic Scoring SystemCommon grade 3Phase 2 partWorse adverse eventsOpen-label studyProportion of patientsPrognostic scoring systemOverall responseChronic myelomonocytic leukemiaNew therapeutic optionsAmerican medical centersEligible patientsFebrile neutropaeniaIntravenous decitabinePrimary endpointRefractory patientsStudy drugClinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa
Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, Eckert LO, Geerlings SE, Köves B, Hooton TM, Juthani-Mehta M, Knight SL, Saint S, Schaeffer AJ, Trautner B, Wullt B, Siemieniuk R. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clinical Infectious Diseases 2019, 68: 1611-1615. PMID: 31506700, DOI: 10.1093/cid/ciz021.Peer-Reviewed Original ResearchConceptsAsymptomatic bacteriuriaInfectious Diseases SocietyDiseases SocietyHealthy womenSolid organ transplantsClinical practice guidelinesSpinal cord injuryInvasive urologic proceduresNonurologic surgeryUrologic abnormalitiesClinical symptomsPregnant womenCord injuryCurrent guidelinesCommon findingHigh prevalencePractice guidelinesOrgan transplantsOlder womenUrologic proceduresAntimicrobial treatmentAdult populationAntimicrobial useAntimicrobial resistanceWomenClinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa
Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, Eckert LO, Geerlings SE, Köves B, Hooton TM, Juthani-Mehta M, Knight SL, Saint S, Schaeffer AJ, Trautner B, Wullt B, Siemieniuk R. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clinical Infectious Diseases 2019, 68: e83-e110. PMID: 30895288, DOI: 10.1093/cid/ciy1121.Peer-Reviewed Original ResearchConceptsAsymptomatic bacteriuriaInfectious Diseases SocietyDiseases SocietyHealthy womenSolid organ transplantsClinical practice guidelinesSpinal cord injuryInvasive urologic proceduresNonurologic surgeryUrologic abnormalitiesClinical symptomsPregnant womenCord injuryCurrent guidelinesCommon findingHigh prevalencePractice guidelinesOrgan transplantsOlder womenUrologic proceduresAntimicrobial treatmentAdult populationAntimicrobial useAntimicrobial resistanceWomenEffect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia
Ball S, Brown TJ, Das A, Khera R, Khanna S, Gupta A. Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia. American Journal Of Clinical Oncology 2019, 42: 270-274. PMID: 30628912, DOI: 10.1097/coc.0000000000000514.Peer-Reviewed Original ResearchMeSH KeywordsDietHumansInfection ControlInfectionsNeoplasmsNeutropeniaPrognosisRandomized Controlled Trials as TopicConceptsRate of infectionUnrestricted diet groupNeutropenic dietAcute lymphoblastic leukemiaCancer patientsAcute myeloid leukemiaDiet groupInfection rateUnrestricted dietNeutropenic cancer patientsPrimary outcome measureLower patient satisfactionRisk of infectionRandom-effects modelingComprehensive database searchDatabase inceptionLymphoblastic leukemiaPatient satisfactionRestrictive dietsMyeloid leukemiaRelative riskSTUDY SELECTIONOutcome measuresPRISMA guidelinesPatientsSacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal Of Medicine 2019, 380: 741-751. PMID: 30786188, DOI: 10.1056/nejmoa1814213.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnemiaAntibodies, Monoclonal, HumanizedAntigens, NeoplasmAntineoplastic AgentsCamptothecinCell Adhesion MoleculesDiarrheaDose-Response Relationship, DrugFemaleHumansImmunoconjugatesInfusions, IntravenousIrinotecanMaleMiddle AgedNeutropeniaProgression-Free SurvivalSurvival RateTriple Negative Breast NeoplasmsConceptsMetastatic triple-negative breast cancerTriple-negative breast cancerSacituzumab govitecan-hziyProgression-free survivalClinical benefit rateIndependent central reviewBreast cancerResponse rateAdverse eventsOverall survivalCentral reviewBenefit rateHuman trophoblast cell surface antigen 2Refractory metastatic triple-negative breast cancerTrophoblast cell surface antigen 2Median progression-free survivalSN-38Shorter progression-free survivalCell surface antigen 2Blinded independent central reviewDurable objective responsesPrevious anticancer therapyUnacceptable toxic effectsObjective response rateMain adverse reactions
2018
Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
Xu X, Dimopoulos M, Sonneveld P, Ho P, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min C, Schecter J, Jansson R, Zhang L, Sun Y, Clemens P. Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Advances In Therapy 2018, 35: 1859-1872. PMID: 30374808, PMCID: PMC6223994, DOI: 10.1007/s12325-018-0815-9.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDose-Response Relationship, DrugFemaleFinlandHumansLenalidomideMaleMelphalanMiddle AgedMultiple MyelomaNeutropeniaProgression-Free SurvivalThalidomideTreatment OutcomeConceptsProgression-free survivalDaratumumab exposureCombination therapyDosing scheduleMultiple myelomaAdverse eventsMonoclonal antibody targeting CD38Standard-of-care regimensDose of daratumumabNo dose adjustmentCombination therapy regimensPopulation pharmacokinetic analysisExposure-safety relationshipMaximal clinical benefitDisease-related covariatesEfficacy/safety outcomesIntravenous daratumumabResultsPharmacokinetic profilesExposure-response analysesDose adjustmentTherapy regimensClinical benefitDaratumumabExposure-efficacyPivotal studiesDuvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1318-1326. PMID: 30094870, PMCID: PMC8260004, DOI: 10.1002/ajh.25243.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaPhase 1 studyTN patientsRR patientsLymphocytic lymphomaLymphocytic leukemiaRefractory chronic lymphocytic leukemiaMedian response durationAdvanced hematologic malignanciesPhase 3 studyOverall response rateCLL/SLLSmall lymphocytic lymphomaPatient's diarrheaExpansion cohortTransaminase elevationHematologic malignanciesPharmacodynamic activityResponse durationPatientsResponse rateΓ inhibitorDuvelisibDual inhibitorLymphomaAn Initiative to Decrease Time to Antibiotics for Patients With Fever and Neutropenia
Emerson BL, Prozora S, Jacob A, Clark K, Kotrady D, Edwards L, Ciaburri R, Riera A. An Initiative to Decrease Time to Antibiotics for Patients With Fever and Neutropenia. American Journal Of Medical Quality 2018, 34: 158-164. PMID: 30078347, DOI: 10.1177/1062860618792305.Peer-Reviewed Original ResearchConceptsMultidisciplinary teamRapid Plan-DoPediatric emergency departmentStudy-Act cyclesEfficiency of careAntibiotic administrationEmergency departmentVulnerable patientsPlan-DoPatientsNeutropeniaAverage timeFeverInterventionProcess control chartsData reviewDecrease timeAntibioticsSignificant improvementAdministration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply